

Information for Connecticut Prescribers of Prescription Drugs Provided Pursuant to the State of Connecticut's Substitute House Bill No. 6669 Public Act No. 23-171

LENVIMA[®] (lenvatinib) capsules

<u>Legend Drug</u>	<u>WAC Package Price*</u>
Lenvima 4 mg/day Capsule	\$23,444.00 per 30 day carton
Lenvima 8 mg/day (4 mg x 2) Capsule	\$23,444.00 per 30 day carton
Lenvima 10 mg/day (10 mg x 1) Capsule	\$23,444.00 per 30 day carton
Lenvima 12 mg/day (4 mg x 3) Capsule	\$23,444.00 per 30 day carton
Lenvima 14 mg/day (10 mg x 1 and 4 mg x 1) Capsule	\$23,444.00 per 30 day carton
Lenvima 18 mg/day (10 mg x 1 and 4 mg x 2) Capsule	\$23,444.00 per 30 day carton
Lenvima 20 mg/day (10 mg x 2) Capsule	\$23,444.00 per 30 day carton
Lenvima 24 mg/day (10 mg x 2 and 4 mg x 1) Capsule	\$23,444.00 per 30 day carton

For information on the variation efficacy of LENVIMA in different racial and ethnic groups, please see:

- Supplement to: Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. *N Engl J Med* 2015;372:621-30. DOI: 10.1056/NEJMoa1406470.
- Supplement to: Makker V, Colombo N, Casado Herraes A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. *N Engl J Med*. 2022;386(5):437-448. doi:10.1056/NEJMoa2108330.
- Supplement to: Grünwald V, Powles T, Kopyltsov E, et al. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study. *Eur Urol Oncol*. 2023;6(4):437-446. doi:10.1016/j.euo.2023.01.010.

The price patients will pay to acquire the marketed drug is often different than the WAC prices listed, and most patients do not pay WAC. How much a patient will pay will depend on many factors, including the patient's insurance coverage. To find out the exact cost of their prescriptions, patients should contact their health insurance company or preferred pharmacy.

***Wholesale Acquisition Cost (WAC)** as published by FDB represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to FDB by the manufacturer. WAC does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price. FDB does not perform any independent investigation or analysis of actual transaction prices for purposes of reporting WAC. FDB relies on manufacturers to report or otherwise make available the values for the WAC.

For more information about First Databank's drug pricing policy, visit
<https://www.fdbhealth.com/drug-pricing-policy>